Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report: CBD and cannabis withdrawal
Open accessAbstract
WHAT IS KNOWN AND OBJECTIVE: Cannabis withdrawal in heavy users is commonly followed by increased anxiety, insomnia, loss of appetite, migraine, irritability, restlessness and other physical and psychological signs. Tolerance to cannabis and cannabis withdrawal symptoms are believed to be the result of the desensitization of CB1 receptors by THC. CASE SUMMARY: This report describes the case of a 19-year-old woman with cannabis withdrawal syndrome treated with cannabidiol (CBD) for 10 days. Daily symptom assessments demonstrated the absence of significant withdrawal, anxiety and dissociative symptoms during the treatment. WHAT IS NEW AND CONCLUSION: CBD can be effective for the treatment of cannabis withdrawal syndrome.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An inpatient with heavy cannabis dependence and episodes of cannabis withdrawal syndrome treated with CBD yielded positive results.
“Based on findings from animal studies, we treated an inpatient with heavy cannabis dependence and episodes of cannabis withdrawal syndrome with CBD, which yielded positive results (143).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · see citing works
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407 · see citing works
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315 · see citing works
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · see citing works
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · see citing works
Self-citationSafety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 1× · see citing works
“CBD has proven to be a safe drug with no significant adverse effects in humans, even with chronic use(24) and in high doses.(12,25,26) Based on these findings, we investigated the effects of CBD in a subject with cannabis dependence and a history of cannabis withdrawal syndrome.”
BackgroundSelf-citationReview of the Validity and Significance of Cannabis Withdrawal Syndrome
Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. G. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1967 · Cited by 521 · see citing works
Cannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509 · see citing works
Self-citationFusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465 · see citing works
Self-citationCannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works
Self-citationAntianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · see citing works
Self-citationZanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366 · see citing works
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364 · see citing works
Self-citationThe cannabis withdrawal syndrome
Budney, A. J., & Hughes, J. R. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000218592.00689.e5 · Cited by 351 · see citing works
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P. F., Laguna, J., Allender, J. R., Snider, S. R., Stern, L. Z., Sandyk, R., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 324 · see citing works
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works
Self-citationChallenges in Using Opioids to Treat Pain in Persons With Substance Use Disorders
Savage, S. R., Kirsh, K. L., & Passik, S. D. (2008) · Addiction Science & Clinical Practice · doi:10.1151/ascp08424 · Cited by 291 · see citing works
Marijuana Dependence and Its Treatment
Budney, A. J., Roffman, R. A., Stephens, R., & Walker, D. D. (2007) · Addiction Science & Clinical Practice · doi:10.1151/ascp07414 · Cited by 278 · see citing works
Marijuana Withdrawal in Humans: Effects of Oral THC or Divalproex
Haney, M., Hart, C. L., Vosburg, S. K., Nasser, J. A., Bennett, A., Zúbaran, C., & Foltin, R. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300310 · Cited by 262 · see citing works
Cannabinoid tolerance and dependence: A review of studies in laboratory animals
González, S. R., Cebeira, M., & Fernández‐Ruíz, J. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.028 · Cited by 258 · see citing works
Marijuana Abstinence Effects in Marijuana Smokers Maintained in Their Home Environment
Budney, A. J., Hughes, J. R., Moore, B. A., & Novy, P. L. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.917 · Cited by 223 · see citing works
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207 · see citing works
Parker, L. A., Burton, P., Sorge, R. E., Yakiwchuk, C., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1825-7 · Cited by 171 · see citing works
Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.
Cooper, Z. D., & Haney, M. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00095.x · Cited by 158 · see citing works
Villares, J. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.012 · Cited by 134 · see citing works
Tyndale, R. F., Payne, J. I., Gerber, A. L., & Sipe, J. C. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30491 · Cited by 117 · see citing works
Pharmacotherapy for Cannabis Dependence
Vandrey, R. G., & Haney, M. (2009) · CNS Drugs · doi:10.2165/00023210-200923070-00001 · Cited by 109 · see citing works
Stempliuk, V. D. A., Barroso, L. P., de Andrade, A. G., Nicastri, S., & Malbergier, A. (2005) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462005000300006 · Cited by 96 · see citing works
The endocannabinoid system as a target for the treatment of cannabis dependence
Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.018 · Cited by 92 · see citing works
Hypnoticlike effects of cannabidiol in the rat
Monti, J. M. (1977) · Psychopharmacology · doi:10.1007/bf00497858 · Cited by 84 · see citing works
Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers.
Zuardi, A. W., Guimarães, F. S., & Moreira, A. C. (1993) · PubMed · Cited by 76 · see citing works
Self-citationReinforcing effects of oral Δ9-THC in male marijuana smokers in a laboratory choice procedure
Hart, C. L., Haney, M., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2234-2 · Cited by 58 · see citing works
The nonpsychoactive cannabis constituent cannabidiol is a wake-inducing agent.
Murillo‐Rodríguez, E., Millán‐Aldaco, D., Palomero‐Rivero, M., Mechoulam, R., & Drucker-Colı́n, R. (2008) · Behavioral Neuroscience · doi:10.1037/a0013278 · Cited by 45 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- Zanelati TV, Biojone C, Moreira FA, Gui- maraes FS, Joca SR. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol, 2010;159:122-128.
- Consroe P, Laguna J, Allender J et al. Con- trolled clinical trial of cannabidiol in Hun- tington's disease. Pharmacol Biochem Behav, 1991;40:701-708.
- First MB, Spitzer RL, Gibbon M, Williams JBM, eds. 1997. Structured clinical interview for DSM-IV axis I disorders -Clinican ver- sion (SCID-CV). Washington D.C: Ameri- can Psychiatry Press.
Cited by
Sorted by citations
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645 · see citing works
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 479 · see citing works
Freeman, T. P., & WINSTOCK, A. R. (2015) · Psychological Medicine · doi:10.1017/s0033291715001178 · Cited by 310 · see citing works
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works
Self-citationGarcía-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306 · see citing works
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 282 · see citing works
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266 · see citing works
A systematic review of cannabidiol dosing in clinical populations
Millar, S., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O’Sullivan, S. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14038 · Cited by 246 · see citing works
The cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221 · see citing works
Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30290-x · Cited by 202 · see citing works
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Bonaccorso, S., Ricciardi, A., Zangani, C., Chiappini, S., & Schifano, F. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.08.002 · Cited by 170 · see citing works
Cannabidiol reduces ethanol consumption, motivation and relapse in mice
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Navarrón, C. M., Morales‐Calero, M. I., Navarrete, F., Torres‐Suárez, A. I., & Manzanares, J. (2017) · Addiction Biology · doi:10.1111/adb.12495 · Cited by 152 · see citing works
Englund, A., Freeman, T. P., Murray, R. M., & McGuire, P. K. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30075-5 · Cited by 151 · see citing works
Elsaid, S., Kloiber, S. M., & Foll, B. L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.005 · Cited by 136 · see citing works
Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence
Prud'homme, M., Cata, R., & Jutras‐Aswad, D. (2015) · Substance Abuse Research and Treatment · doi:10.4137/sart.s25081 · Cited by 133 · see citing works
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Chye, Y., Christensen, E., Solowij, N., & Yücel, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00063 · Cited by 128 · see citing works
Trigo, J. M., Soliman, A., Quilty, L. C., Fischer, B., Rehm, J. T., Selby, P. L., Barnes, A. J., Huestis, M. A., George, T. P., Streiner, D. L., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190768 · Cited by 123 · see citing works
Brents, L. K., & Prather, P. L. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.839700 · Cited by 115 · see citing works
Greydanus, D. E., Hawver, E. K., Greydanus, M. M., & Merrick, J. (2013) · Frontiers in Public Health · doi:10.3389/fpubh.2013.00042 · Cited by 112 · see citing works
Nabiximols for the Treatment of Cannabis Dependence
Lintzeris, N., Bhardwaj, A. K., Mills, L., Dunlop, A. J., Copeland, J., McGregor, I. S., Bruno, R., Gugusheff, J., Phung, N., Montebello, M. E., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.1993 · Cited by 111 · see citing works
The therapeutic role of Cannabidiol in mental health: a systematic review
Khan, R. A., Naveed, S., Mian, N., Fida, A., Raafey, M. A., & Aedma, K. K. (2020) · Journal of Cannabis Research · doi:10.1186/s42238-019-0012-y · Cited by 97 · see citing works
Mandolini, G. M., Lazzaretti, M., Pigoni, A., Oldani, L., Delvecchio, G., & Brambilla, P. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000239 · Cited by 89 · see citing works
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Zlebnik, N. E., & Cheer, J. F. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014038 · Cited by 79 · see citing works
Batalla, A., Janssen, H., Gangadin, S. S., & Bossong, M. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071058 · Cited by 77 · see citing works
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
Navarrete, F., García‐Gutiérrez, M. S., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.626010 · Cited by 78 · see citing works
Review: Cannabinoids as Medicinals
Khalsa, J. H., Bunt, G. C., Blum, K., Maggirwar, S. B., Galanter, M. S., & Potenza, M. N. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00438-3 · Cited by 72 · see citing works
Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study
de Meneses-Gaya, C., Crippa, J. A. S., Hallak, J. E. C., Miguel, A. C., Laranjeira, R., Bressan, R. A., Zuardi, A. W., & Lacerda, A. L. T. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1416 · Cited by 59 · see citing works
Self-citationProgress toward pharmacotherapies for cannabis-use disorder: an evidence-based review
Copeland, J., & Pokorski, I. (2016) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s89857 · Cited by 56 · see citing works
The therapeutic potential of purified cannabidiol
O’Sullivan, S. E., Jensen, S. S., Nikolajsen, G. N., Bruun, H. Z., Bhuller, R., & Hoeng, J. (2023) · Journal of Cannabis Research · doi:10.1186/s42238-023-00186-9 · Cited by 56 · see citing works
Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report.
Shannon, S. M., & Opila-Lehman, J. (2015) · PubMed Central · Cited by 56 · see citing works
Novel Pharmacologic Approaches to Treating Cannabis Use Disorder
Balter, R. E., Cooper, Z. D., & Haney, M. (2014) · Current Addiction Reports · doi:10.1007/s40429-014-0011-1 · Cited by 54 · see citing works
Cannabidiol in the context of substance use disorder treatment: A systematic review
Paulus, V., Billieux, J., Benyamina, A., & Karila, L. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107360 · Cited by 47 · see citing works
THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
Pintori, N., Caria, F., Luca, M. A. D., & Miliano, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065251 · Cited by 48 · see citing works
Is there a role for cannabidiol in psychiatry?
Khoury, J. M., das Neves, M. D. C. L., Roque, M. A. V., Queiroz, D. A. D. B., de Freitas, A. A. C., de Fátima, Â., Moreira, F. A., & Garcia, F. D. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1285049 · Cited by 45 · see citing works
Cannabidiol and substance use disorder: Dream or reality
Karimi‐Haghighi, S., Razavi, Y., Iezzi, D., Scheyer, A. F., Manzoni, O. J., & Haghparast, A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108948 · Cited by 45 · see citing works
Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.
Nona, C. N., Hendershot, C. S., & Foll, B. L. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000272 · Cited by 41 · see citing works
Fischer, B., Kuganesan, S., Gallassi, A. D., Malcher‐Lopes, R., van den Brink, W., & Wood, E. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.09.005 · Cited by 39 · see citing works
Navarrete, F., Aracil-Fernández, A., & Manzanares, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14226 · Cited by 38 · see citing works
Anooshe, M., Nouri, K., Karimi‐Haghighi, S., Mousavi, Z., & Haghparast, A. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113158 · Cited by 38 · see citing works
Alviz-Amador, A., Contreras‐Puentes, N., & Mercado‐Camargo, J. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107590 · Cited by 38 · see citing works
Narayan, A. J., Downey, L. A., Manning, B., & Hayley, A. C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104941 · Cited by 36 · see citing works
Pinto, J. V., Saraf, G., Frysch, C., Vigo, D., Keramatian, K., Chakrabarty, T., Lam, R. W. M., Kauer‐Sant’Anna, M., & Yatham, L. N. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719895195 · Cited by 36 · see citing works
Cannabis use, harms and the management of cannabis use disorder
Copeland, J., Clement, N., & Swift, W. (2014) · Neuropsychiatry · doi:10.2217/npy.13.90 · Cited by 31 · see citing works
Frequent cannabis users demonstrate low knowledge of cannabinoid content and dosages
Kruger, D. J., Kruger, J. S., & Collins, R. L. (2020) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2020.1752150 · Cited by 31 · see citing works
Kibret, B. G., Canseco-Alba, A., Onaivi, E. S., & Engidawork, E. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1137957 · Cited by 30 · see citing works
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01086-1 · Cited by 22 · see citing works
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Dammann, I., Rohleder, C., & Leweke, F. M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2228-6118 · Cited by 23 · see citing works
Alegre-Zurano, L., Berbegal-Sáez, P., Luján, M. Á., Cantacorps, L., Martín‐Sánchez, A., García-Baos, A., & Valverde, O. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112708 · Cited by 15 · see citing works
Harm to Others from Substance Use and Abuse: The Underused Potential in Nationwide Registers
Lund, I. O., & Bukten, A. (2015) · Substance Abuse Research and Treatment · doi:10.4137/sart.s23545 · Cited by 18 · see citing works
Tijani, A. O., Garg, J., Frempong, D., Verana, G., Kaur, J., Joga, R., Sabanis, C. D., Kumar, S., Kumar, N., & Puri, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.034 · Cited by 17 · see citing works
Pacheco, J. C., Souza, J. D. S., Hallak, J. E. C., Osório, F. D. L., Campos, A. C., Guimarães, F. S., Zuardi, A. W., & Crippa, J. A. S. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001405 · Cited by 16 · see citing works
Self-citationAnxiety Modulation by Cannabinoids—The Role of Stress Responses and Coping
Haller, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115777 · Cited by 17 · see citing works
Cannabinoid concentrations in Canada's regulated medical cannabis industry
Mammen, G., de Freitas, L., Rehm, J. T., & Rueda, S. (2017) · Addiction · doi:10.1111/add.13738 · Cited by 16 · see citing works
Basavarajappa, B. S., & Subbanna, S. (2024) · Biomolecules · doi:10.3390/biom14101296 · Cited by 13 · see citing works
Liu, L., Li, J., Wang, C., Xu, Y., Leung, C., Yang, G., Lin, S., Zhang, S., Tan, Y., Zhang, H., et al. (2022) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2022.2073450 · Cited by 12 · see citing works
Cannabidiol and 5-HT1A Receptors
Fogaça, M. V., Campos, A. C., & Guimarães, F. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800213-1.00070-5 · Cited by 11 · see citing works
Bhardwaj, A. K., Mills, L., Doyle, M., Sahid, A., Montebello, M., Monds, L., Arunogiri, S., Haber, P., Lorenzetti, V., Lubman, D. I., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05616-3 · Cited by 10 · see citing works
Dyck, G. J. B., Maayah, Z. H., Eurich, D. T., & Dyck, J. R. B. (2021) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgab053 · Cited by 9 · see citing works
Cannabidiol in the Management of In-Patient Cannabis Withdrawal: Clinical Case Series
Pokorski, I., Clement, N., Phung, N., Weltman, M., Fu, S., & Copeland, J. (2017) · Future Neurology · doi:10.2217/fnl-2016-0035 · Cited by 9 · see citing works
Souza, A. J., Guimarães, F. S., & Gomes, F. V. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114504 · Cited by 8 · see citing works
Cyclic Vomiting Syndrome and Cannabis Hyperemesis Syndrome
Lathrop, J. R., Rosen, S. N., Heitkemper, M. M., & Buchanan, D. T. (2023) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000730 · Cited by 6 · see citing works
Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?
Fernandes, J. A. B., Filev, R., & Fidalgo, T. M. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0065 · Cited by 6 · see citing works
Cannabidiol for the Treatment of Drug Use Disorders
SANTOS, R. G. D., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00113-7 · Cited by 5 · see citing works
Self-citationOliver, D., Englund, A., Chesney, E., Chester, L. A., Wilson, J., Sovi, S., Wigroth, S., Hodsoll, J. P., Strang, J., Murray, R. M., et al. (2023) · Addiction · doi:10.1111/add.16353 · Cited by 5 · see citing works
Treatment of Cannabis Use Disorders
Ramesh, D., & Haney, M. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_14 · Cited by 5 · see citing works
Overview of Current State-of-the-Art Treatments for Cannabis Use Disorders, and Future Directions
Copeland, J., Pokorski, I., & Gibson, L. (2017) · Current Addiction Reports · doi:10.1007/s40429-017-0151-1 · Cited by 5 · see citing works
Cogan, P. S. (2020) · Journal of Dietary Supplements · doi:10.1080/19390211.2020.1769246 · Cited by 5 · see citing works
Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder
Gendy, M. N. S., Frey, B. N., Ameringen, M. V., Kuhathasan, N., & MacKillop, J. M. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad031 · Cited by 5 · see citing works
Evaluation of anxiety-like behaviors following ethanol withdrawal in mice: effects of cannabidiol
Coltri, L. P., Bonassoli, V. T., Milani, H., & de Oliveira, R. M. W. (2020) · Acta Scientiarum Health Sciences · doi:10.4025/actascihealthsci.v42i1.53001 · Cited by 3 · see citing works
A nutraceutical role for cannabidiol. Why not?
Pierro, F. D. (2015) · Nutrafoods · doi:10.1007/s13749-015-0037-6 · Cited by 3 · see citing works
Cannabinoids for the treatment of cannabis abuse disorder
Rodríguez, A., & Zavala, C. (2018) · Medwave · doi:10.5867/medwave.2018.06.7286 · Cited by 3 · see citing works
Canabidiol e suas indicações em psiquiatría
Ramírez, J. F. M. (2021) · Revista Digital Palabra (Universidad Pontificia Bolivariana) · doi:10.18566/medupb.v40n1.a09 · Cited by 3 · see citing works
Briânis, R. C., Moreira, F. A., & Iglesias, L. P. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.03.006 · Cited by 2 · see citing works
Cannabidiol in the Treatment of Mood Disorders
Pinto, J. V., Ziak, M. L., Schaffer, A., & Yatham, L. N. (2022) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-022-00265-3 · Cited by 2 · see citing works
Cannabinoids and drug addiction
Luca, M. A. D., & Fattore, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00012-6 · Cited by 2 · see citing works
Cannabidiol and Cannabis Use Disorder
García‐Gutiérrez, M. S., Navarrete, F., Viudez‐Martínez, A., Gasparyan, A., Caparrós, E., & Manzanares, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-90365-1_5 · Cited by 2 · see citing works
The good face of Cannabis sativa: Cannabidiol
Evren, C. (2019) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2019.00041 · Cited by 2 · see citing works
Legalisation and Liberalisation of Cannabis: The Benefits and Drawbacks of the Global Trend
Fasesan, O. (2022) · Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria) · doi:10.30442/ahr.0803-01-168 · Cited by 1 · see citing works
Cannabinoid for alcohol use disorder
Marquez, J. D., Dezanetti, T., Walz, R., & de Carvalho, C. R. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.08.005 · Cited by 1 · see citing works
Ross, J. A., Riccardelli, W., Robitaille, J., & Levy, S. (2025) · Adolescents · doi:10.3390/adolescents5040054 · Cited by 1 · see citing works
Pasic, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-58260-3_42 · Cited by 1 · see citing works
Spelta, L. E. W., Real, C. C., Bruno, V., Buchpiguel, C. A., Garcia, R. C. T., Torres, L. H., Faria, D. D. P., & Marcourakis, T. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25327 · Cited by 1 · see citing works
THERAPEUTIC POTENTIAL OF CANNABIDIOL: THE MOST IMPORTANT ACHIEVEMENTS ON THE WAY TO A NEW ERA
Shevchuk, M. M., & Volos, L. I. (2023) · Medical Science of Ukraine (MSU) · doi:10.32345/2664-4738.2.2023.17 · Cited by 1 · see citing works
Cannabidiol effects on cocaine-seeking behaviour and incubation of craving in micePreprint
Alegre-Zurano, L., Luján, M. Á., Cantacorps, L., Martín‐Sánchez, A., García-Baos, A., & Valverde, O. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.18.423391 · Cited by 1 · see citing works
Karl, T., & Arnold, J. C. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.026
With pot now legal, therapies sought to blunt high of marijuana
Owens, B. (2014) · Nature Medicine · doi:10.1038/nm0214-107
Pan, J. (2016) · TSpace (University of Toronto)
Ferreira, J. V., Correa, L. C., da Costa, D. C., & Hage-Melim, L. I. D. S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82184
Cannabidiol-mediated regulation of spontaneous cannabinoid withdrawal
Navarrete, F., Aracil-Fernández, A., Gasparyan, A., & Manzanares, J. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.727
The use of cannabidiol in addiction therapy in the light of clinical trials.
Lewandowska, J. A., Kapała, J. M., & Puchała, Ł. (2020) · Farmacja Polska · doi:10.32383/farmpol/127827
Substance dependence and abuse
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.024
Cannabis de grado médico para el tratamiento de la dependencia a Δ-9-Tetrahidrocannabinol
Pavlovsky, F., Groisman, R., Hurtado, A. K., & García, L. (2022) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v33i157.265
Wolinsky, D. I., & Vandrey, R. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89862-1.00037-4
MICROSCOPIC ARCHITECTURE OF THE LIVER OF EXPERIMENTAL RATS AFTER CANNABIDIOL OIL APPLICATIONS
Shevchuk, M. M., & Volos, L. I. (2023) · Polonia University Scientific Journal · doi:10.23856/5845
Rabbani, A. J., & Rabbani, R. R. (2020) · Journal of Emerging Investigators · doi:10.59720/20-062
Cannabidiol for Treatment of Child and Adolescent Psychiatric Disorders
Melnyk, C., & Wagner, K. D. (2024) · Psychiatric annals · doi:10.3928/00485713-20240320-01
Substance Use Disorders and the Endocannabinoid System: A New Narrative
García‐Gutiérrez, M. S., Torregrosa, A. B., Rueda, F. N., Gasparyan, A., Esteve, L. G., Navarro, D., & Manzanares, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_140-1
Substance Use Disorders and the Endocannabinoid System: A New Narrative
García‐Gutiérrez, M. S., Torregrosa, A. B., Rueda, F. N., Gasparyan, A., Esteve, L. G., Navarro, D., & Manzanares, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_140 · Cited by 1 · see citing works
de Pontes, L. R., & Ribeiro, S. T. G. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.001
- Authors
- Crippa, J. A. S., Hallak, J. E. C., Machado-de-Sousa, J. P., Queiroz, R. H. C., Bergamaschi, M., Chagas, M. H. N., & Zuardi, A. W.
- Affiliations
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Universidade de São Paulo (BR)
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2012-10-24
- Volume
- 38
- Issue
- 2
- Pages
- 162-164
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W1889449076
- Cited by
- 101
- References
- 33
- Citations by year
- 2025: 3 · 2024: 9 · 2023: 13 · 2022: 10 · 2021: 7 · 2020: 10 · 2019: 12 · 2018: 6 · 2017: 10 · 2016: 4 · 2015: 8 · 2014: 7 · 2013: 2
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Clinical Pharmacy and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
- Keywords
- cannabidiol, cannabis withdrawal syndrome, anxiety, dissociative symptoms, insomnia, cannabis use disorder
- MeSH terms
- Adult, Cannabidiol, Cannabis, Female, Humans, Substance Withdrawal Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
